Evofem Biosciences, Inc. Affirms 2022 Guidance. Evofem continues to expect net product sales in the range of $30 to $35 million for its 2022 fiscal year, representing 264% to 325% growth year-over-year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0108 USD | -8.47% |
|
-18.18% | -83.12% |
May. 16 | Transcript : Evofem Biosciences, Inc. - Special Call | |
May. 15 | Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-83.12% | 852K | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Affirms 2022 Guidance